Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Equity Average (2020 - 2025)

Cytek Biosciences' Equity Average history spans 6 years, with the latest figure at $360.2 million for Q4 2025.

  • For Q4 2025, Equity Average fell 7.79% year-over-year to $360.2 million; the TTM value through Dec 2025 reached $360.2 million, down 7.79%, while the annual FY2025 figure was $368.7 million, 6.51% down from the prior year.
  • Equity Average reached $360.2 million in Q4 2025 per CTKB's latest filing, down from $378.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $424.5 million in Q1 2023 to a low of -$7.5 million in Q1 2021.
  • Average Equity Average over 5 years is $348.8 million, with a median of $391.9 million recorded in 2024.
  • Peak YoY movement for Equity Average: skyrocketed 8298.01% in 2022, then dropped 7.79% in 2025.
  • A 5-year view of Equity Average shows it stood at $404.3 million in 2021, then grew by 4.14% to $421.0 million in 2022, then fell by 3.97% to $404.3 million in 2023, then decreased by 3.39% to $390.6 million in 2024, then decreased by 7.79% to $360.2 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Equity Average are $360.2 million (Q4 2025), $378.1 million (Q3 2025), and $378.6 million (Q2 2025).